The mainstay for the treatment of multi-vessel severe coronary artery disease is coronary artery bypass graft (CABG) surgery. Various grafts and conduits have been used and were studied to optimize surgical outcomes. The internal mammary artery (IMA) is the gold-standard conduit and associated with significant improvement in short and long-term outcomes and survival of patients undergoing CABG surgery.
The saphenous vein graft (SVG), also commonly used in CABG procedure, is prone to early atherosclerotic changes that lead to obstruction. Therefore it is considered inferior to the IMA conduit in terms of long-term patency rates. In comparison to SVGs, the long-term patency rate of IMA bypass conduits is very high, and around 90% of grafts remain free of significant stenosis at ten years.
Loop et al. published 10-year survival of patients who received an IMA graft to the left anterior descending coronary artery with or without one or more vein grafts versus patients who received only SVGs, which showed that the survival was higher with an IMA graft (93.4%) versus SVG (88.0%) for those with the one-vessel disease, 90.0% versus 79.5% for two-vessel disease, and 82.6% versus 71.0% (P<0.0001) for those with three-vessel disease. Since then, the IMA has become the preferred choice for grafting the left anterior descending coronary artery in CABG. Specific physiological, anatomic, and hemodynamic characteristics of IMA graft make it a suitable conduit and less prone to early atherosclerotic changes. We will discuss the anatomy of IMA, the surgical technique of IMA grafting, its complications, and clinical significance.
The internal mammary artery (IMA), also called the internal thoracic artery, supplies the anterior chest wall and the breast. Although the IMA usually has a separate origin from the subclavian artery, it may have a common origin with the thyrocervical trunk. After arising from the subclavian artery, it runs anterior to the pleural cupola and crosses the brachiocephalic vein underneath. It then runs posterior to the sternoclavicular joint and costal cartilages and anterior to the parietal pleura. At the third intercostal space (ICS), it enters the space between the transversus thoracis and the intercostal muscles and gives off branches to intercostal spaces. When it reaches the seventh costal cartilage, IMA divides into the superior epigastric artery and the musculophrenic artery.
Histologically, the IMA is a muscular artery that makes it susceptible to spasm when handled surgically. However, because its media is thinner and less muscular than other arteries and veins, the IMA produces a higher basal and stimulated rate of nitric oxide (vasodilator) and exhibits a lower propensity for spasm. The IMA is also found to be less prone to atherosclerosis as compared to venous grafts. This could be a result of the non-fenestrated internal elastic lamina of the IMA, which is less susceptible to intimal hyperplasia, which contributes to the development of atherosclerosis.
The diameter of the IMA is relatively smaller as compared to venous grafts, and the mean flow velocity in IMA is about three times that in saphenous venous grafts. High flow velocities, low thrombotic threshold velocity, resistance to the development of atherosclerosis, the release of vascular endothelial growth factor, and reactivity to vasodilators are some of the factors responsible for the long term patency of IMA bypass. That is why the use of IMA to revascularize the left anterior descending artery has a significant impact on repeat revascularization and significantly reduces the chances of re-do coronary artery bypass.
A review of indications for coronary artery bypass graft (CABG) surgery is beyond the scope of this article. We present guideline recommendations for the use of the internal mammary artery (IMA) as the graft of choice for CABG.
According to the American College of Cardiology/American Heart Association guidelines, indications for CABG using the IMA include the following
Contraindications for coronary artery bypass graft (CABG) using internal mammary artery (IMA) grafts include the following
Most of these listed contraindications are general contraindications for CABG.
Types of equipment for coronary artery bypass graft (CABG) using internal mammary artery (IMA) graft include
Coronary artery bypass graft (CABG) is a complicated and lengthy procedure. A whole team is required to undergo this surgery. Following personnel form the team who will take care of the patient before during and after the procedure.
Operative risk assessment is an integral part of patient preparation. Commonly used risk models to predict perioperative morbidity and mortality include the Euro score system and the Society of Thoracic Surgeons (STS) Risk Model. Variables commonly required for these models include age, previous myocardial infarction, peripheral vascular disease, renal failure, hemodynamic state, and ejection fraction.
The STS model also requires surgical acuity, re-operative status, shock, and chronic lung disease. Aspirin should be continued, especially in those who present with acute coronary syndrome (ACS). For those patients who take P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor) and undergoing elective CABG, these drugs should be stopped for either five days (for clopidogrel) or seven days (for prasugrel) before the procedure. Beta-adrenergic blockers should be continued in the perioperative period unless contraindications exist. Recently, the use of intravenous P2Y12 inhibitor (cangrelor) allowed for earlier CABG operations as cangrelor's antiplatelet effects are very short-acting, and the intravenous infusion can be stopped before CABG.
Each patient should have recommended units of blood, fresh frozen plasma, and platelets cross-matched before the procedure. On the day of the procedure, the patient should have fasting of at least six hours, and intravenous antibiotics should be administered before CABG.
For a standard median sternotomy, the anterior chest is exposed with the patient in a supine position. A roll is placed in the interscapular region to provide better access to the sternum. After general anesthesia induction and intubation, the median sternotomy is performed. The IMA is harvested either directly or as a pedicle. Left IMA is commonly harvested as a pedicle, whereas the right IMA is generally skeletonized because a right IMA pedicle usually interferes with sternal wound healing. To harvest IMA, endothoracic fascia is incised first by using electrocautery. Once the fascia is pulled down with the help of forceps, under-surface of the internal mammary vein is exposed till IMA becomes visible. The cautery tip is used to separate the vein and IMA. Then the trunk of IMA is separated from the chest wall, which allows us to expose and cut the perforating branches. Then IMA is pulled down using curved DeBakey forceps, and surrounding tissue is separated from the IMA. Mediastinal branches are divided, and the skeletonized extra-pleural IMA is then harvested from its origin from the subclavian artery. The fascia is peeled off the ITA while the internal thoracic veins are left in situ to preserve a certain degree of vascularisation of the sternum.
After harvesting the conduit, the patient is put on cardiopulmonary bypass (in on-pump CABG) by cannulating the aorta and right atrium. Aorta is cannulated at the soft and nonatherosclerotic area after giving unfractionated heparin and lowering systolic blood pressure below 100mmHg. Once the aortic cannula is in place, it is made air-free and connected to the arterial pump tubing. Then venous cannula is inserted into the right atrial appendage. Aorta is clamped distal to the cannula, and cardioplegia is infused via the aortic cannula.
After starting the cardiopulmonary bypass, the distal coronary bypass targets on the disease native coronary arteries are identified. The left IMA is usually anastomosed to the left anterior descending artery (ramus intermedius, diagonal branches), and right IMA is anastomosed to either left circumflex or right coronary artery (also ramus intermedius, obtuse marginal, posterior descending and right posterolateral). An incision is given in the distal coronary artery, and then the conduit ostium is sutured around the full circumference of the anastomosis using a 7-0 or 8-0 polypropylene suture. Grafting is done sequentially. Hemostasis is confirmed before the release of the aortic clamp. The chest wound is closed, and a drain is usually placed. The patient is monitored in the immediate postoperative period in the cardiothoracic intensive care unit.
Complications during and after the coronary artery bypass grafting (CABG) in general include
Cerebrovascular accidents are reported in about 1% of patients having IMA bypass graft and mainly determined by underlying risk factors, including diabetes mellitus, advanced age, prior CVA, aortic atherosclerosis, and peripheral arterial disease.
Although the sternal wound infection rate has significantly reduced, however, it is relatively more common in patients with obesity, diabetes mellitus, and advanced age.
The most common perioperative arrhythmia is atrial fibrillation, which can be managed with beta-blockers, amiodarone, and anticoagulation. It is associated with embolic stroke and increases perioperative mortality.
Robust data and literature suggest that the internal mammary artery (IMA) undergoes minimal atherosclerotic changes and has excellent long term outcomes and patient survival compared to superior vena cava graft (SVG). Its survival and patency rates are much better as compared to venous and even other arterial grafts. Hence the IMA graft is considered to be the first choice conduit and the gold standard for coronary artery bypass graft.
The coronary artery bypass graft (CABG) is a complicated surgical procedure that requires operative skills and expertise as well as good perioperative care. Therefore it is necessary to have a system to ensure the completion of all aspects of patient care. In pre-operative care, in addition to discussing the risks and benefits of the procedure with the patient and family, the assessment must be done to ensure that patient meets the recommended criteria for the procedure. Proper sterile technique is fundamental to better outcomes.
In the postoperative period, patients need regular monitoring by trained nursing staff for complications. After recovery, every patient should undergo cardiac rehabilitation. It is now recommended to have a multidisciplinary team approach that may include a primary care provider, intervention cardiologist, cardiac surgeon, cardiac rehabilitation specialist, a cardiac nurse, and a cardiac pharmacist to enhance patient care, optimize procedural success and minimize perioperative complications.
|||Gaudino M,Taggart D,Suma H,Puskas JD,Crea F,Massetti M, The Choice of Conduits in Coronary Artery Bypass Surgery. Journal of the American College of Cardiology. 2015 Oct 13; [PubMed PMID: 26449144]|
|||Loop FD,Lytle BW,Cosgrove DM,Stewart RW,Goormastic M,Williams GW,Golding LA,Gill CC,Taylor PC,Sheldon WC, Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. The New England journal of medicine. 1986 Jan 2; [PubMed PMID: 3484393]|
|||Cameron A,Davis KB,Green G,Schaff HV, Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period. The New England journal of medicine. 1996 Jan 25; [PubMed PMID: 8531997]|
|||Edwards FH,Clark RE,Schwartz M, Impact of internal mammary artery conduits on operative mortality in coronary revascularization. The Annals of thoracic surgery. 1994 Jan; [PubMed PMID: 7904145]|
|||Berger A,MacCarthy PA,Siebert U,Carlier S,Wijns W,Heyndrickx G,Bartunek J,Vanermen H,De Bruyne B, Long-term patency of internal mammary artery bypass grafts: relationship with preoperative severity of the native coronary artery stenosis. Circulation. 2004 Sep 14; [PubMed PMID: 15364835]|
|||He GW, Arterial grafts for coronary artery bypass grafting: biological characteristics, functional classification, and clinical choice. The Annals of thoracic surgery. 1999 Jan; [PubMed PMID: 10086578]|
|||Otsuka F,Yahagi K,Sakakura K,Virmani R, Why is the mammary artery so special and what protects it from atherosclerosis? Annals of cardiothoracic surgery. 2013 Jul [PubMed PMID: 23977631]|
|||Hefel L,Schwabegger A,Ninković M,Wechselberger G,Moriggl B,Waldenberger P,Anderl H, Internal mammary vessels: anatomical and clinical considerations. British journal of plastic surgery. 1995 Dec; [PubMed PMID: 8548151]|
|||Dobrin P,Canfield T,Moran J,Sullivan H,Pifarré R, Coronary artery bypass. The physiological basis for differences in flow with internal mammary artery and saphenous vein grafts. The Journal of thoracic and cardiovascular surgery. 1977 Sep; [PubMed PMID: 302374]|
|||Takeuchi K,Sakamoto S,Nagayoshi Y,Nishizawa H,Matsubara J, Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2004 Nov; [PubMed PMID: 15519189]|
|||Hillis LD,Smith PK,Anderson JL,Bittl JA,Bridges CR,Byrne JG,Cigarroa JE,DiSesa VJ,Hiratzka LF,Hutter AM Jr,Jessen ME,Keeley EC,Lahey SJ,Lange RA,London MJ,Mack MJ,Patel MR,Puskas JD,Sabik JF,Selnes O,Shahian DM,Trost JC,Winniford MD,Jacobs AK,Anderson JL,Albert N,Creager MA,Ettinger SM,Guyton RA,Halperin JL,Hochman JS,Kushner FG,Ohman EM,Stevenson W,Yancy CW, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. The Journal of thoracic and cardiovascular surgery. 2012 Jan; [PubMed PMID: 22172748]|
|||Shahian DM,O'Brien SM,Filardo G,Ferraris VA,Haan CK,Rich JB,Normand SL,DeLong ER,Shewan CM,Dokholyan RS,Peterson ED,Edwards FH,Anderson RP, The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. The Annals of thoracic surgery. 2009 Jul; [PubMed PMID: 19559822]|
|||Cheng K,Rehman SM,Taggart DP, A Review of Differing Techniques of Mammary Artery Harvesting on Sternal Perfusion: Time for a Randomized Study? The Annals of thoracic surgery. 2015 Nov; [PubMed PMID: 26410160]|
|||Serruys PW,Morice MC,Kappetein AP,Colombo A,Holmes DR,Mack MJ,Ståhle E,Feldman TE,van den Brand M,Bass EJ,Van Dyck N,Leadley K,Dawkins KD,Mohr FW, Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. The New England journal of medicine. 2009 Mar 5; [PubMed PMID: 19228612]|
|||Matros E,Aranki SF,Bayer LR,McGurk S,Neuwalder J,Orgill DP, Reduction in incidence of deep sternal wound infections: random or real? The Journal of thoracic and cardiovascular surgery. 2010 Mar; [PubMed PMID: 20018307]|